- Home
- INMB vs PTMN Comparison
INMB vs PTMN Comparison
Compare INMB & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- PTMN
- Stock Information
- Founded
- INMB 2015
- PTMN 2006
- Country
- INMB United States
- PTMN United States
- Employees
- INMB N/A
- PTMN N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- PTMN Finance: Consumer Services
- Sector
- INMB Health Care
- PTMN Finance
- Exchange
- INMB Nasdaq
- PTMN Nasdaq
- Market Cap
- INMB 176.5M
- PTMN 142.6M
- IPO Year
- INMB 2019
- PTMN N/A
- Fundamental
- Price
- INMB $7.32
- PTMN $12.03
- Analyst Decision
- INMB Strong Buy
- PTMN Hold
- Analyst Count
- INMB 3
- PTMN 1
- Target Price
- INMB $24.33
- PTMN $14.00
- AVG Volume (30 Days)
- INMB 272.9K
- PTMN 69.6K
- Earning Date
- INMB 05-08-2025
- PTMN 05-08-2025
- Dividend Yield
- INMB N/A
- PTMN 18.03%
- EPS Growth
- INMB N/A
- PTMN N/A
- EPS
- INMB N/A
- PTMN N/A
- Revenue
- INMB $14,000.00
- PTMN $62,432,000.00
- Revenue This Year
- INMB N/A
- PTMN N/A
- Revenue Next Year
- INMB N/A
- PTMN $4.14
- P/E Ratio
- INMB N/A
- PTMN N/A
- Revenue Growth
- INMB N/A
- PTMN N/A
- 52 Week Low
- INMB $4.32
- PTMN $11.60
- 52 Week High
- INMB $12.72
- PTMN $20.84
- Technical
- Relative Strength Index (RSI)
- INMB 46.72
- PTMN 25.73
- Support Level
- INMB $7.14
- PTMN $11.60
- Resistance Level
- INMB $7.78
- PTMN $12.90
- Average True Range (ATR)
- INMB 0.71
- PTMN 0.57
- MACD
- INMB 0.00
- PTMN -0.05
- Stochastic Oscillator
- INMB 54.59
- PTMN 14.88
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.